SWOG clinical trial number
S1600
A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Closed
Phase
Accrual
100%
Abbreviated Title
Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Status Notes
S1600 study will be permanently closed to accrual, effective 10/20/2023.
Activated
02/21/2019
Closed
10/20/2023
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG
Research committees
Symptom Control and Quality of Life
Genitourinary Cancer
Treatment
Placebo
Immune-modulating drink
Eligibility Criteria Expand/Collapse
Tissue diagnosis of primary cell carcinoma of the bladder by TURBT or partial cystectomy. No evidence of unresectable disease or metastatic disease as assessed by exam under anesthesia or imaging (CT, MRI, PET). Plans for the cystectomy to be performed within 28 days after registration. Surgery must be planned to be performed under pre-approved, study-specific surgical guidelines (see Section 7.3). Must have completed any neoadjuvant chemotherapy or immunotherapy (intravesical or systemic) >/= 14 calendar days prior to registration and any toxicities resolved to at least Grade 2. May have a history of radiation therapy. Radiation therapy must have been completed >/= 180 days prior to registration. May have a history of prior partial cystectomy. Prior partial cystectomy must have been completed at least 180 days prior to registration. Must not have planned adjuvant chemotherapy within 90 days after radical cystectomy. >/= 18 years of age. Must be able to swallow liquid and have no refractory nausea, vomiting, malabsorption, or significant small bowel resection that would preclude adequate absorption. Patients on tube feeding are not eligible. Must have baseline nutrition status assessed using the Scored Patient-Generated Subjective Global Assessment (PG-SGA) by a clinician or licensed healthcare practitioner within 14 days prior to registration and must not have a global category rating of Stage C (severely malnourished). Must not have galactosemia. Must not have known active viral infections such as human immunodeficiency virus (HIV) or hepatitis, as these chronic viral infections may cause cachexia and immunodeficiency and thus alter the biology regarding the study endpoints. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Prostate cancer found at cystectomy would not be considered a prior malignancy. Must not be pregnant or nursing as the conditions preclude candidacy for radical cystectomy. Must consent and be willing to have specimens collected and submitted as described in Section 15.1. must be offered the opportunity to participate in additional specimen banking as outlined in Section 15.2. Must consent and provide their telephone contact information for four 24-hour dietary recall phone interviews to be conducted by staff at the Exercise, Diet, Genitourinary, & Endocrinology Laboratory (EDGE) Research Laboratory (see Sections 7.1c, 7.7e, and 15.3). Must be able to understand and speak English and/or Spanish because the dietary recall phone interviews will only be conducted in English or Spanish.
Publication Information Expand/Collapse
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase